Multiple roles of Ring 1 and YY1 binding protein in physiology and disease

Shaohua Zhan a, b, Tianxiao Wang c, Wei Ge b, *, Jinming Li a, *

a National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing, China
b National Key Laboratory of Medical Molecular Biology & Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China
c Key Laboratory of Carcinogenesis and Translational Research, Department of Head and Neck Surgery, Peking University Cancer Hospital & Institute, Beijing, China

Received: September 26, 2017; Accepted: November 16, 2017

Introduction

RYBP was first identified in 1999 using a yeast two-hybrid screen to identify novel members of the polycomb group proteins (PcGs) in mammals [1]. The human RYBP protein contains 228 amino acids, and its structure includes a conserved Npl4 Zinc finger (NZF) motif at the N-terminus, a central region that is characteristically enriched with arginine and lysine residues and a C-terminal region enriched with serine and threonine amino acids. Over nearly 20 years, multiple studies have found that RYBP functions as an organ developmental adaptor. There is also evidence that RYBP regulates the expression of different genes involved in various aspects of biological processes, via a mechanism that is dependent on interactions with components of PcG complexes and/or through binding to different transcriptional factors. In addition, RYBP interacts directly or indirectly with apoptosis-associated proteins to mediate anti-apoptotic or pro-apoptotic activity in both the cytoplasm and nucleus of various cell types. Furthermore, RYBP has also been shown to act as tumour suppressor gene in different solid tumours, but as an oncogene in lymphoma and melanoma. In this review, we summarize our current understanding of the functions of this multifaceted RYBP in physiological and pathological conditions, including embryonic development, apoptosis and cancer, as well as its role as a component of polycomb repressive complex 1.

Keywords: RYBP ● development ● apoptosis ● cancer ● PRC1

Abstract

Ring 1 and YY1 binding protein (RYBP) was first identified in 1999, and its structure includes a conserved Npl4 Zinc finger motif at the N-terminus, a central region that is characteristically enriched with arginine and lysine residues and a C-terminal region enriched with serine and threonine amino acids. Over nearly 20 years, multiple studies have found that RYBP functions as an organ developmental adaptor. There is also evidence that RYBP regulates the expression of different genes involved in various aspects of biological processes, via a mechanism that is dependent on interactions with components of PcG complexes and/or through binding to different transcriptional factors. In addition, RYBP interacts directly or indirectly with apoptosis-associated proteins to mediate anti-apoptotic or pro-apoptotic activity in both the cytoplasm and nucleus of various cell types. Furthermore, RYBP has also been shown to act as tumour suppressor gene in different solid tumours, but as an oncogene in lymphoma and melanoma. In this review, we summarize our current understanding of the functions of this multifaceted RYBP in physiological and pathological conditions, including embryonic development, apoptosis and cancer, as well as its role as a component of polycomb repressive complex 1.

Introduction

RYBP was first identified in 1999 using a yeast two-hybrid screen to identify novel members of the polycomb group proteins (PcGs) in mammals [1]. The human RYBP protein contains 228 amino acids, and its structure includes a conserved Npl4 Zinc finger (NZF) motif at the N-terminus, a central region that is characteristically enriched with arginine and lysine residues and a C-terminal region enriched with serine and threonine amino acids [2]. The N-terminus of this protein is evolutionarily conserved among different species, including Homo sapiens, Mus musculus and Drosophila melanogaster [3]. Bejarano et al. demonstrated that RYBP shares 80% similarity and 72% identity in the N-termini and 80% similarity and 70% identity in the C-termini among RYBP orthologues [4]. In the past, nearly 20 years, multiple studies have been conducted to investigate the various functions of RYBP. Reports indicated that RYBP is a
multifunctional protein, which binds several transcriptional factors and components of polycomb repressive complex 1 (PRC1), and is associated with development, as well as apoptosis and cancer. Therefore, Neira and colleagues attempted to provide a structural explanation for the participation of RYBP in these pleiotropic processes. They demonstrated that RYBP is a rare native unfolded protein lacking well-defined secondary or tertiary structure, which acquires a well-structured conformation through binding various macromolecular complexes [5]. In this review, we will comprehensively summarize the recent progress in our understanding of the mechanisms underlying the functions of this multifaceted RYBP in the various biological processes and diseases mentioned. Although RYBP has been reported previously using several different names, including DEDAF, YEAF1 and AAP-1 [6–8], the term of RYBP is used exclusively in this review.

The roles of RYBP in development

This first description of RYBP expression in relation to development was in 1999. Garcia et al. demonstrated that RYBP transcripts were expressed mainly in the developing central nervous system, as well as in the branchial arch, forelimb buds, tail bud and hindgut at mouse embryonic day 9.0 (E9.0), although at E9.5, RYBP was broadly expressed in nearly all tissues throughout the embryo [1]. These findings were consistent with the expression of RYBP in very early embryos in Drosophila [4]. Furthermore, RYBP knockout mice exhibited lethality at the early post-implantation stage [9], and homozygous null mutant Drosophila died progressively, with 43% dying during embryogenesis and 44% during larval/pupal development [10]. An important study associated with RYBP function in nerve development was reported by Pinty and colleagues [9] who reported that RYBP plays a dose-dependent role in central nervous system development. RYBP heterozygous null embryos exhibited aberrant brain development, including disrupted neural tube closure, forebrain overgrowth and exencephaly [9]. In further investigations of the underlying mechanisms, they also demonstrated that RYBP impaired the differentiation of pluripotent embryonic stem cells (ESCs) to mature neural cell types, including neurons, astrocytes and oligodendrocytes, through up-regulation of the neural marker Pax 6 and down-regulation of Plagl1 [11]. Furthermore, the same group showed that RYBP is repressed by direct miR-29 binding to the 3'-UTR of the RYBP protein, whereas the RYBP and YY1 complex were found to co-occupy miR-29 gene promoters and repress its expression. This study indicated the existence of a RYBP-miR-29 feedback loop that may play a key role in skeletal myogenesis [14]. During reprogramming, loss of DDX5 acted as a promoter of somatic cell reprogramming by repressing miR-125b expression, which in turn, resulted in the RYBP up-regulation [15]. Intriguingly, enhanced RYBP not only suppressed lineage-specific genes by increasing monoubiquitination of histone H2A at lysine-119 (H2A1K119ub1) levels through PRC1, but also activated pluripotency-promoting genes by facilitating the recruitment of OCT4 to the Kdm2b promoter [15]. Thus, this study suggested that DDX5 controlled reprogramming through the PRC1-dependent and PRC1-independent functions of RYBP. In addition, RYBP was found to suppress pre-implantation- and germline-specific genes, indicating a role for RYBP in epigenetic resetting during pre-implantation development [16]. Taken together, these reports suggest that RYBP performs multiple functions as a developmental adaptor. However, evidence for some aspects of the function of RYBP in development is extremely preliminary and the precise underlying mechanisms remain to be fully elucidated.

The roles of RYBP in the regulation of gene expression through the PcG complex and binding with transcriptional factors

PcGs are transcriptional repressors that participate in cancer epigenetics, stem cell self-renewal, X chromosome inactivation, imprinting and multicellular development [17], which was first identified in D. melanogaster as regulators in silencing homeotic (Hox) gene and normal developmental body patterning [18]. PcGs are categorized into two multi-subunit protein complexes, PRC1 and polycomb repressive complex 2 (PRC2). PRC2 catalyses the trimethylation of the lysine 27 residue of histone H3 (H3K27me3) via histone methyltransferase EZH1/2, while PRC1 adds a single ubiquitin molecule to the lysine 119 residue of histone H2A via RING1A/B E3 ligase [19]. The canonical repressive model indicates that, when targeted to specific loci, PRC1 and PRC2 usually co-occupy target sites in the genome, including the multiple PRC1 and PRC2 complexes, H3K27me3 and H2AK119ub1 [20]. The canonical PRC1 comprises four core protein families, PGF (PGF1–6), CBX (CBX2/4/6/7/8), PHC (PHC1/2/3) and RING1A/B, which are necessary for their respective enzymatic activities [21]. RYBP was first identified as a component of PRC1 complexes in 1999 and shown to act as a transcriptional repressor through reporter gene assays [1]. Using GST pull-down assays, Garcia et al. demonstrated that RYBP interacts specifically with RING1A via its C-terminal region and with YY1 and M33/CBX2, an interactor of RING1A proteins, via two
and that PRC1 complexes can be divided into six groups (PRC1.1 that RYBP plays a critical role in the function of PRC1 complexes [22] mutation did not cause homeotic transformations [10]. In contrast to trithorax (trxG) complexes, based on the observation that the RYBP acting protein, it does not represent a core component of the PcG and ous phenotypes, including defects in syncytial nuclear divisions, as well as reduced wing sizes. However, this report indicated that, although RYBP may be an interacting protein, it does not represent a core component of the PcG and trithorax (trxG) complexes, based on the observation that the RYBP mutation did not cause homeotic transformations [10]. In contrast to this study, Gao and coworkers used proteomic assays to demonstrate that RYBP plays a critical role in the function of PRC1 complexes [22] and that PRC1 complexes can be divided into six groups (PRC1.1–PC1.6) according to the different PCGs [22]. The subunits of RYBP/ YAF2 mutually exclude CBX, PHC and SCM components in PRC1.2 and PRC 1.4, which bear the closest similarity with the canonical PRC1 complex. This result was consistent with the report that RYBP competes with CBX7 for RING1B [23, 24]. Of particular note, they found that RYBP exhibited more enzymatic activity in H2AK119 than CBX2 or CBX8 in the PRC 1.4 group [22]. In contrast to the classification of PRC1 based on PCG subunits, Tavares et al. indicated the coexistence of two different types of PRC1 in ESCs that differ in the mutually exclusive presence of RYBP or CBX7 [24]. CBX7-PRC1 requires the H3K27me3 modification to localize to chromatin and plays a critical role in the maintenance of pluripotency in ESCs [24, 25]. However, lineage specification during ESC differentiation is mediated by CBX7 repression via the CBX2 and CBX4 subunits within PRC1 [25]. In contrast to CBX-PRC1, RYBP-PRC1 comprises four core components (RYBP, RING1B, PHC1 and PCGF2/ME18) and occupancy on chromatin is independent of H3K27me3 [24]. Furthermore, Morey et al. also showed that RYBP-PRC1 and CBX7-PRC1 were not only localized in a wide range of overlapping genomic regions, but also targeted specific genes to exert different biological function in ESCs [26]. Due to the low levels of RING1B and H2AK119ub1 in RYBP-PRC1 target genes, expression of these genes is significantly higher than that of CBX7-PRC1 target genes. Furthermore, RYBP targets are associated with the M phase of meiosis and cellular metabolism, whereas CBX7 targets are more commonly involved in developmental processes and cell differentiation [26]. Additionally, one informative study performed by Rose and coworkers [27] to clarify inconsistencies in the evidence for RYBP stimulation of E3 ligase activity in PRC1 [22, 24, 26] demonstrated that RYBP stimulates E3 ligase activity in both PCGF1-RING1B and PCGF4-RING1B dimers in vitro, although that activity of the PCGF1-RING1B catalytic dimer in H2AK119ub1 was inherently higher than that of PCGF4- RING1B [27]. Moreover, this group showed that RYBP not only stimulated the H2AK119ub1 modification at PRC1 target sites but also regulated PRC2 activity in modifying H3K27me3 at polycomb target sites; however, RYBP deletion did not significantly affect global levels of H2AK119ub1 and H3K27me3 [27] and the exact mechanism underlying the function of different RYBP-PRC1 complexes in gene transcription remains to be clarified.

In addition to its role as a subunit in the PRC1 complex, it has been shown that RYBP also functions as a component of B6 complex (BcoR) complexes, which contain both PcG and Skp–Cullin– F-box subcomplexes [28, 29]. Regarding PcG subcomplexes, RYBP is included in NSPC1/PCGF1, RING1A and RING1B proteins [30]. Gearhart et al. also demonstrated that BcoR complexes, including RYBP, are recruited to silence B6l targets gene, such as PS3 and Cyclin D2, to regulate apoptosis and cell cycle [28]. Furthermore, two studies indicated that RYBP also functions as a novel ubiquitin-binding protein, not only binding to RING1B [23], but also to its substrate, histone H2A [3]. However, Rose et al. demonstrated that the capacity of RYBP in PCGF1-PRC1 to recognize ubiquitin did not result in the high levels of H2AK119ub1 [27].

In addition to its function as a transcriptional repressor dependent on the PRC1 complexes, RYBP also functions as a transrepressor through binding to different transcription factors. Using a yeast two-hybrid system and immortalization assays, Sawa and coworkers demonstrated that RYBP and its homologue YAF2 interacted with hGABP that both in vitro and in vivo. However, hGABP’s transcriptional activity was repressed by RYBP and activated by YAF2 and the underlying mechanism still needs to be investigated [6]. In accordance with this observation, using a two-hybrid screen assay, two teams also showed that RYBP interacts specifically with E2F2, E2F3 and E2F6 in a manner that was dependent on the conserved marked box domain [31, 32]. Additionally, Trimarchi and colleagues indicated the existence of a physical interaction between E2F6 and various PcG proteins, including RYBP, RING1A, BMI1/PCGF4, ME18/PCGF2 and MPH-1, and that these complexes act as repressors of gene transcription. In contrast, Schlisio et al. demonstrated that the interaction of RYBP with both E2F2/E2F3 and YY1 provided a functional complex for transcriptional activation of genes, such as Cdc6. Taken together, these reports demonstrate that RYBP regulates the expression of different genes involved in various aspects of biological processes, via a mechanism that is dependent on interactions with components of PcG complexes and/or through binding to different transcriptional factors (Fig. 1).

The roles of RYBP in the apoptosis

Apoptosis is an evolutionarily conserved cell suicide process that is stimulated in response to a variety of stimuli [33] and plays critical roles in different biological processes and diseases, including embryonic development and cell differentiation, normal cell turnover and immunological processes, as well as neurodegenerative diseases and various types of cancer [34]. One of our understanding mechanisms of apoptosis induction is through death receptors, such as CD95/Fas [35]. The cytoplasmic tail of CD95 can interact with several death effector domain (DED)-containing proteins to form the death-inducing signalling complex (DISC), which enhances CD95-mediated apoptosis [36]. These DED-containing proteins residing in the cytoplasmic DISC includes FADD, caspase-8 and/or caspase-10 [37]. Using a yeast
two-hybrid assay, Zheng et al. demonstrated that RYBP not only interacts with FADD, caspase-8 and caspase-10, but also augments the formation of DISC, promoting CD95-mediated apoptosis [7]. In addition, RYBP can directly interact with another DED-containing DNA-binding protein (DEDD) in the nucleus, resulting in the diffuse distribution of DEDD in the nucleoplasm and facilitating DEDD-mediated apoptosis through activation of caspase-6 [7, 38]. Collectively, this evidence demonstrates that RYBP regulates apoptosis in both the nucleus and the cytoplasm through DED-containing proteins. Moreover, through constructing a cytoplasm-located RYBP mutant (RYBPmut), one study indicated that RYBPmut has enhanced potential to promote tumour apoptosis and inhibit tumour cell proliferation via p53-dependent and caspase-8-dependent mechanisms compared with wild-type RYBP [2]. In addition, Stanton et al. reported that RYBP not only plays a pivotal role in the interaction between Hip1 protein interactor (Hippi) and caspase-8 [39], but also enhances Hippi-mediated apoptosis via caspase-8. This report also suggested that RYBP-Hippi-caspase-8 may function specifically in brain development [39]. Intriguingly, Danen-van Oorschot et al. found that RYBP overexpression induced apoptosis in imaginal discs cells via a mechanism that was dependent on the pro-apoptotic reaper, Hid and Grim proteins, as well as dFADD and DREDD (mammalian homologues of FADD and caspase-8, respectively) [46]. Furthermore, under stress conditions, RYBP-induced apoptosis required the epigenetic adaptor trxG, which not only induced apoptosis, but also promoted reaper protein expression. Thus, stress-induced apoptosis requires the coaction of RYBP and trxG [46]. However, in contrast to the pro-apoptotic activity, Fereres and colleagues found that RYBP in Drosophila interacted directly with the SCF complex, including its core component skpA, dCul1 and slmb, to form the RYBP-SCF complex that inhibited both developmental and X-ray-induced apoptosis by regulating the expression of reaper and apoptosis protein 1 (DIAP1) in a ubiquitin-dependent manner [47]. These findings indicated that the RYBP-SCF complex exerts anti-apoptotic activity in Drosophila. This contradiction could be due to the interaction of RYBP with several apoptosis-related proteins. Taken together, these studies indicate that RYBP interacts directly or indirectly with apoptosis-associated proteins to mediate anti-apoptotic or pro-apoptotic activity in both the cytoplasm and nucleus of various cell types (Fig. 2).
The roles of RYBP in the cancer

It has been reported that PcG proteins play pivotal roles in regulating the balance between proliferation and differentiation during normal development. Deregulation of PcG proteins disrupts this balance and often contributes to cell transformation and neoplasticity [48, 49]. As mentioned previously, RYBP is a multifaceted adaptor involved in both the PcG complex and apoptosis; indeed, several studies have demonstrated dysregulated expression of RYBP in various human tumour tissues, including prostate, lung, liver, breast and cervical cancers, as well as Hodgkin’s lymphoma (HL), and glioblastoma multiforme [43, 50–57]. Here, we will discuss the function of RYBP in these different types of cancer.

In comprehensive studies of the expression of PcG proteins in various human cancers compared with their non-cancerous cell counterparts, two groups found that RYBP expression was up-regulated in tumours, including oligodendroglia tumours, pituitary adenoma, HL and T cell lymphoma [58, 59]. Furthermore, Sánchez-Beato and colleagues demonstrated that RYBP was overexpressed in 55% of classical forms of HL, but was absent in normal lymphoid tissue and lymphocyte-predominant HL [57]. In addition, RYBP expression in HL was positively associated with unfavourable treatment response and poor overall survival. Although the precise role of RYBP overexpression in these tumours is still unclear, these studies indicated that RYBP may act as an oncogene [57]. In contrast, because RYBP is located on the chromosome band 3p, an integrative genomic profile showed that RYBP was frequently down-regulated in cervical cancer and prostate cancer due to the loss of 3p. These results indicate that RYBP also functions as a tumour suppressor [51–53]. In addition, the decrease in RYBP expression in cervical cancer was positively related to poor progression-free survival. This study indicated a pathogenic role for the loss of RYBP in malignant progression of cervical cancer and chemoradiosensitivity [51]. Furthermore, gene ontology analysis revealed that loss of the candidate 3p target genes in cervical cancer was enriched in the biological processes and pathways of apoptosis, proliferation and stress response [52]. In prostate cancer, TMPRSS2-ERG was the most prevalent somatic mutation and appeared to be an early event in the progression of prostate cancer [60]. Several reports demonstrated that TMPRSS2-ERG fusion was linked to deletions on chromosome 3p14, including the FOXP1, SHQ1 and RYBP genes [53, 54, 61]. Furthermore, 3p14 deletions correlated positively with advanced stage, high Gleason grade and PTEN deletion in prostate cancer, implicating RYBP as a tumour suppressor gene. Ectopic overexpression of RYBP has also been shown to inhibit proliferation of the prostate BPH-1 and PC-3 cell lines [54]. In accordance with the function of RYBP in cervical and prostate cancers, several studies have also demonstrated significantly decreased expression of RYBP at both the mRNA and protein levels in tumorous tissues compared with the corresponding adjacent normal tissues in patients with lung cancer, hepatocellular carcinoma (HCC) and breast cancer; this reduction was also observed in cell lines derived from these types of cancer compared with corresponding non-tumorous cell lines [55, 56].
| Cancer types                      | RYBP expression in human cancers | Clinical functions                        | Target                                      | Cell lines/models                                   | Action and function                                                                                   | References |
|----------------------------------|----------------------------------|-------------------------------------------|---------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------|------------|
| T cell leukaemia/                | Up-regulation                    | (+) Unfavourable treatment response       | Unknown                                    | --                                                  | Unknown                                                                                             | [57–59]    |
| Hodgkin’s lymphoma               |                                  | (+) Poor overall survival                 | Unknown                                    | --                                                  | Unknown                                                                                             |            |
| Cervical cancer                  | Down-regulation                  | (−) Poor progression-free survival        | Unknown                                    | --                                                  | Unknown                                                                                             | [51, 52]   |
|                                  |                                  | (−) Chemoradioresistance                  | Unknown                                    | --                                                  | Unknown                                                                                             |            |
| Prostate cancer                  | Down-regulation                  | (−) Advanced stage                        | Unknown                                    | BPH-1/PC-3 cell lines                               | Inhibition of growth ability                                                                       | [53, 54, 61]|
|                                  |                                  | (−) High Gleason grade                    | Unknown                                    |                                                     |                                                                                                     |            |
| Breast cancer                    | Down-regulation                  | (−) Disease-free survival                 | Cyclin A/cyclin B                          | SK-BR-3/ZR-75-1/T47D/MDA-MB-231/MCF-7 cell lines BALB/c nude mice | Suppression of cell growth, migration and invasion                                                | [63]       |
|                                  |                                  |                                          | E-cadherin snail SRRM3 and downstream REST-003 |                                                     |                                                                                                     |            |
| Lung cancer                      | Down-regulation                  | (−) Histological subtype                  | BAX PARP                                   | A549/H1299/H358/H838/BEAS-2B/HCC827/PC9/NCI-H358/NCI-H1965/NCI-H1975 cell lines nude mice | Inhibition of growth ability in vitro and in vivo; induction of cell apoptosis; inhibition of cell migration and invasion | [55, 64]   |
|                                  |                                  | (−) Tumour infiltration                   | Caspase-8                                  |                                                     |                                                                                                     |            |
|                                  |                                  | (−) TNM stage                              | Caspase-10 Vimentin                        |                                                     |                                                                                                     |            |
|                                  |                                  | (−) Shorter overall survival               | E-cadherin EGFR-ERK/AKT                    |                                                     |                                                                                                     |            |
|                                  |                                  | (−) Chemosensitivity                      |                                             |                                                     |                                                                                                     |            |
| Hepatocellular carcinoma         | Down-regulation                  | (−) Poor differentiation                  | BAX PARP                                   | HepG2/Hep3B/Huh7/SMMC-7721/MHC097L/MHC097/HMCLLM3/ CL48/HEK293A cell lines nude mice | Inhibition of growth in vitro and in vivo; induction of cell apoptosis; inhibition of cell migration and invasion | [43, 62, 65]|
|                                  |                                  | (−) Increased serum γGT                  | PARP p53                                   |                                                     |                                                                                                     |            |
|                                  |                                  | (−) Poor recurrence-free survival          | Vimentin                                   |                                                     |                                                                                                     |            |
|                                  |                                  | (−) Poor overall survival                  | E-cadherin ZEB1/ZEB2                       |                                                     |                                                                                                     |            |
| Melanoma                         | Unknown                          | Unknown                                   | WM1791C and WM209 cell lines               |                                                     | Promotion of cell proliferation, migration and invasion                                             | [68]       |

(+) Positive correlation; (−) negative correlation. SRRM3, serine/arginine repetitive matrix 3; REST, RE1-silencing transcription; PARP, poly [ADP-ribose] polymerase 1; EGFR, epidermal growth factor receptor; ZEB, zinc finger E-box binding homeobox.
Moreover, the low expression of RYBP was also associated with poor prognosis in these patients with cancer.

In breast cancer, Zhou and coworkers found that RYBP overexpression impeded growth and metastasis both in cell lines and nude mice by regulating the protein levels of cyclin A and cyclin B1, as well as E-cadherin and SRRM3-REST-003 [63]. In lung cancer, Voruganti et al. demonstrated that RYBP up-regulation reduced cell proliferation, decreased colony formation and induced apoptosis by activating BAX, as well as PARP, caspase-8 and caspase-10 cleavages. Furthermore, adenovirus-mediated overexpression of RYBP sensitized lung cancer cells to paclitaxel-induced apoptosis both in vitro and in vivo [55]. Dinglin and colleagues also indicated that ectopic RYBP expression impeded cancer cell proliferation and tumour progression via the EGFR-ERK/AKT signalling pathway, as well as inhibiting lung cancer metastasis by reversing epithelial–mesenchymal transition (EMT) [64]. Remarkably, the same group found that, in addition to the function of RYBP in lung cancer, high RYBP expression in HCC also impeded cell proliferation and invasion, induced apoptosis and promoted the cisplatin-mediated chemotherapy both in vitro and in vivo, while RYBP knockdown had the opposite effect [62]. Equally, RYBP can be induced by antitumour drugs (paclitaxel and cisplatin) to synergistically increase apoptosis of tumour cells in lung cancer and HCC [55, 62]. Additionally, in HCC, RYBP was also negatively correlated with the up-regulated expression of ZEB1 and ZEB2 proteins, which was associated with EMT transition. This study indicated that RYBP may also participate in the metastasis of HCC [65]. Of note, Zhao et al. demonstrated that sequence variation/polymorphisms or CpG dinucleotide methylation in the RYBP promoter was not the main contributors to the down-regulated expression of RYBP in HCC. However, they found that transcription factor KLF4 promoted while SP1 inhibited RYBP transcription in HCC cell lines [66]. Intriguingly, Zhu et al. also demonstrated that five RYBP polymorphisms (rs17009699, rs4676875, rs4532099, rs12956 and rs2118593) played a pivotal role in the development of HCC [67]. Of these, rs12956 was associated with longer overall survival, whereas rs2118593 was identified as a risk factor and candidate biomarker of poor prognosis [67]. In contrast, Zhao and coworkers showed that siRNA-mediated RYBP silencing inhibited the proliferation, migration and invasion of melanoma cells, indicating that RYBP may be an oncogene in melanoma [68]. Additionally, the expression of RYBP in melanoma cells was negatively regulated by miR-9-5p, which was suppressed by the RYBP binding protein, YY1. Thus, this study suggested that the YY1–miR-9–RYBP axis plays a vital role in melanoma tumorigenesis [68].

In addition to the roles of RYBP in the particular types of cancer already discussed (Table 1), one study demonstrated histone deacetylase (HDAC)-mediated down-regulation of RYBP in v-Fos-transformed cells, while transient or stable re-expression of RYBP in Fos-transformed cells specifically promoted cell invasion/3-D migration without affecting cell morphology, chemotaxis, migration and proliferation [69]. Furthermore, RYBP was up-regulated in the breast cancer cell line SKBR-3 after treatment with the HDAC inhibitor LAQ824 by inducing the miR-27a down-regulation [50]. Zhao et al. demonstrated that activation of the Notch downstream signalling molecule miR-125a stimulated M1 polarization by suppressing F1H1 and inhibited M2 polarization by down-regulating IRF4 simultaneously, with miR-125a amplifying its own expression via RYBP and the YY1 proteins [70]. This report indicated that RYBP in the Notch-miR-125a signalling pathway may be important in macrophage function, which has been recognized to participate in tumour initiation, growth, invasion and metastasis [71].

In combination, evidence suggests that RYBP acts as tumour suppressor gene in different solid tumours but as an oncogene in lymphoma and melanoma (Fig. 2); however, the precise underlying mechanisms of these opposing function remain to be clarified. Thus, further investigations of the regulation and function of RYBP in different tumour types will provide a greater understanding of the fundamental roles of RYBP in carcinogenesis and cancer progression.

Concluding remarks

Since the first discovery of RYBP in 1999, there has been marked progress in understanding its functions in physiological and pathological conditions, including embryonic development, apoptosis and cancer, as well as its role as a component of PRC1. Moving forward, various important issues associated with the role of RYBP in its biological functions and the underlying molecular mechanisms need to be investigated. These issues include the following: (1) the significance of the conserved NZF motif among different species in the N-terminal of RYBP. Although Arrigoni et al. demonstrated that the ubiquitinated histone H2A was the target of its NZF-ubiquitin-binding domain [3], it was dispensable for its interaction with other components of PRC1 complexes, as well as its repressor activity [1]. Thus, the precise functions of this conserved domain remain to be elucidated in the future. (2) Although numerous RYBP binding proteins have been identified in various cellular and biochemical analyses, global screening of additional RYBP-interactive partners using proteomics strategies is needed to clearly investigate its function in dual roles under different conditions [72–74]. (3) Further studies are required to understand the different activities of the distinct PRC1 complexes in exerting diverse biological functions, given that RYBP appears to associate with different PRC1 complexes. (4) Due to the function of RYBP as a tumour suppressor gene or oncogene in different types of cancer, it is important to clarify the molecular mechanisms by which the effects of RYBP are ‘good’ or ‘bad’ in different microenvironments such as matrix metalloproteinases in cancer progression [75]. Collectively, further studies to investigate the molecular mechanisms by which RYBP interacts with all possible binding proteins involved in different biological processes will pave the way for the development of new therapeutic interventions in human diseases.

Acknowledgements

This work was supported by CAMS Innovation Fund for Medical Sciences (2016-12M-1-003), the National Science Foundation of Beijing Municipality (No. 7164295), the National Natural Science Foundation of China (No. 81601841 and No. 81772273) and Beijing Municipal Administration of Hospital Youth Program (No. QML20161103).

Conflict of interest

The authors confirm that there is no conflict of interests.
References

1. Garcia E, Marcos-Gutierrez C, del Mar Lorente M, et al. RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. EMBO J. 1999; 18: 3404–18.

2. Tan K, Zhang X, Cong X, et al. Tumor suppressor RYBP harbors three nuclear localization signals and its cytoplasm-located mutant exerts more potent anti-cancer activities than corresponding wild type. Cell Signal. 2017; 29: 127–37.

3. Arrigonii R, Alam SL, Wamstad JA, et al. The Polycomb-associated protein Rybp is a ubiquitin binding protein. FEBS Lett. 2006; 580: 6233–41.

4. Bejarano F, Gonzalez I, Vital M, et al. The Drosophila RYBP gene functions as a Polycomb-dependent transcriptional repressor. Mech Dev. 2005; 122: 1118–29.

5. Neira JL, Roman-Trufero M, Contreras LM, et al. The transcriptional repressor RYBP is a natively unfolded protein which folds upon binding to DNA. Biochemistry. 2009; 48: 1548–60.

6. Sawa C, Yoshikawa T, Matsuda-Suzuki F, et al. YEAF1/RYBP and YAF-2 are functionally distinct members of a cofactor family for the YY1 and E4TF1/hGABP transcription factors. J Biol Chem. 2002; 277: 22484–90.

7. Zheng L, Schickling O, Peter ME, et al. The death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Mol Cell Biol. 2001; 21: 31945–52.

8. Danen-van Oorschot AA, Voskamp P, Seelem MC, et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ. 2004; 11: 564–73.

9. Pirity MK, Locker J, Schreiber-Agus N. Rybp/DDAF is required for early postimplantation and for central nervous system development. Mol Cell Biol. 2005; 25: 7193–202.

10. Gonzalez I, Aparicio R, Busturia A. Functional characterization of the dRYBP gene in Drosophila. Genetics. 2008; 179: 1373–88.

11. Kovacs G, Szabo V, Pirity MK. Absence of Rybp compromises neural differentiation of embryonic stem cells. Stem Cells Int. 2016; 2016: 4034620.

12. Pirity MK, Wang WL, Wolf LV, et al. Rybp, a polycomb complex-associated protein, is required for mouse eye development. BMC Dev Biol. 2007; 7: 39.

13. Uijlhely O, Szabo V, Kovacs G, et al. Lack of Rybp in mouse embryonic stem cells impairs cardiac differentiation. Stem Cells Dev. 2015; 24: 2193–205.

14. Zhou L, Wang L, Lu L, et al. A novel target of microRNA-29, Ring1 and YY1-binding protein (Rybp), negatively regulates skeletal myogenesis. J Biol Chem. 2012; 287: 25255–65.

15. Li H, Lai P, Jia J, et al. RNA Helicase DDXX inhibits reprogramming to pluripotency by miRNA-based repression of RYBP and its PRCI-dependent and -independent functions. Cell Stem Cell. 2017; 20: 462–77.

16. Hisada K, Sanchez C, Endo TA, et al. RYBP represses endogenous retroviruses and preimplantation- and germ line-specific genes in mouse embryonic stem cells. Mol Cell Biol. 2012; 32: 1139–49.

17. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009; 10: 691–708.

18. Lewis EB. A gene complex controlling segmentation in Drosophila. Nature. 1978; 276: 595–70.

19. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010; 7: 299–313.

20. Blackledge NP, Rose NR, Klose RJ. Targeting polycomb systems to regulate gene expression: modifications to a complex story. Nat Rev Mol Cell Biol. 2015; 16: 643–9.

21. Schwartz YB, Pirrotta V. A new world of polycombs: unexpected partnerships and emerging functions. Nat Rev Genet. 2013; 14: 853–64.

22. Gao Z, Zhang J, Bonasio R, et al. Pcgf homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell. 2012; 45: 344–56.

23. Wang R, Taylor AB, Leal BZ, et al. Polycomb group targeting through different binding partners of RING1B C-terminal domain. Structure. 2010; 18: 966–75.

24. Tavares L, Dimitrova E, Oxley D, et al. RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell. 2012; 148: 664–78.

25. Morey L, Pascual G, Cozzuto L, et al. Nonoverlapping functions of the Polycomb group Cbx family of proteins in embryonic stem cells. Cell Stem Cell. 2012; 10: 47–62.

26. Morey L, Aloia L, Cozzuto L, et al. RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells. Cell Rep. 2013; 3: 60–9.

27. Rose NR, King HW, Blackledge NP, et al. RYBP stimulates PRC1 to shape chromatin-based communication between Polycomb repressive complexes. Elife. 2016; 5: pii: e18591.

28. Gearhart MD, Corcoran CM, Wamstad JA, et al. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol Cell Biol. 2006; 26: 6880–9.

29. Sánchez C, Sánchez I, Demmers JA, et al. Proteomics analysis of Ring1B/Rn2 interactors identifies a novel complex with the Bfx110/Jhdn1b histone demethylase and the B6c interacting compressor. Mol Cell Proteomics. 2007; 6: 820–34.

30. Comet I, Risling EM, Leblanc B, et al. Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer. 2016; 16: 803–10.

31. Trimmer J, Fairchild B, Wen J, et al. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci USA. 2001; 98: 1519–24.

32. Schlisio S, Halperin T, Vidal M, et al. Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J. 2002; 21: 5775–86.

33. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998; 281: 1305–8.

34. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35: 495–516.

35. Schulze-Osthoff K, Ferrari D, Los M, et al. Apoptosis signaling by death receptors. FEBS J. 1998; 254: 439–59.

36. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000; 288: 2354–7.

37. Barnhart BC, Lee JC, Alapat EC, et al. The death effector domain protein family. Oncogene. 2003; 22: 8634–44.

38. Schickling O, Stegh A, Byrd J, et al. Nuclear localization of DEDD leads to caspase-6 activation through its death effector domain and
inhibition of RNA polymerase I dependent transcription. Cell Death Differ. 2001; 8: 1157.

39. Stanton SE, Blanck JK, Locker J, et al. Rybp interacts with Hippi and enhances Hippi-mediated apoptosis. Apoptosis. 2007; 12: 2197–206.

40. Danen-Van Oorschot A, Fischer D, Grimbergen JM, et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA. 1997; 94: 5843–7.

41. Ma W, Zhang X, Li M, et al. Proapoptotic Rybp interacts with FARK1 and induces small tumor cell apoptosis through the AP-1 signaling pathway. Cell Signal. 2016; 28: 779–87.

42. Novak RL, Phillips AG. Adenoviral-mediated Rybp expression promotes tumor cell-specific apoptosis. Cancer Gene Ther. 2008; 15: 713–22.

43. Chen D, Zhang J, Li M, et al. Rybp stabilizes p53 by modulating MDM2. EMBO Rep. 2009; 10: 166–72.

44. Muller PA, Vousten KH. p53 mutations in cancer. Nat Cell Biol. 2013; 15: 2–8.

45. Amaral JD, Xavier JM, Steer CJ, et al. Targeting the p53 pathway of apoptosis. Curr Pharm Des. 2010; 16: 2493–503.

46. Gonzalez I, Busturia A. High levels of dRybp induce apoptosis in Drosophila imaginal cells through the activation of reaper and the requirement of trithorax, dredd and dFADD. Cell Res. 2009; 19: 747–57.

47. Fereres S, Simon R, Busturia A. A novel dRybp-SF complex functions to inhibit apoptosis in Drosophila. Apoptosis. 2013; 18: 1500–12.

48. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6: 846–56.

49. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer. 2009; 9: 773–84.

50. Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Can Res. 2006; 66: 1277–81.

51. Lando M, Holden M, Bergersen LC, et al. Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet. 2009; 5: e1000719.

52. Lando M, Wilting SM, Snipstad K, et al. Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J Pathol 2013; 230: 59–69.

53. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18: 11–22.

54. Krohn A, Seidel A, Burkhart L, et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol. 2013; 231: 130–41.

55. Voruganti S, Xu F, Qiu J, et al. Rybp predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Lett. 2015; 369: 386–95.

56. Li G, Warden C, Zhou Z, et al. Altered expression of polycomb group genes in glioblastoma multiforme. PLoS ONE. 2013; 8: e80970.

57. Sánchez-Beato M, Sanchez E, Garcia JF, et al. Abnormal PcG protein expression in Hodgkin’s lymphoma. Relation with E2F6 and NFκB transcription factors. J Pathol. 2004; 204: 528–37.

58. Sanchez-Beato M, Sanchez E, Gonzalez-Carrero J, et al. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol. 2006; 19: 684–94.

59. Sasaki D, Imaiumi Y, Hasegawa H, et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica. 2011; 96: 712–9.

60. Kron KJ, Murison A, Zhou S, et al. TMPRS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat Genet. 2017; 49: 1336-45.

61. Feilk E, Schwierter N, Baijer A, et al. Integrative analysis of prostate cancer aggressiveness. Prostate. 2013; 73: 1413–26.

62. Wang W, Cheng J, Qin JJ, et al. Rybp expression is associated with better survival of patients with hepato cellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo. Oncotarget. 2014; 5: 11604–19.

63. Zhou H, Li J, Zhang Z, et al. RING1 and YY1 binding protein suppresses breast cancer cell growth and metastasis. Int J Oncol. 2016; 49: 2442–52.

64. Dinglin X, Ding L, Li G, et al. Rybp inhibits progression and metastasis of lung cancer by suppressing EGFR signaling and epithelial-mesenchymal transition. Transl Oncol. 2017; 10: 280–7.

65. Zhu X, Yan M, Luo W, et al. Expression and clinical significance of PcG-associated protein Rybp in hepatocellular carcinoma. Oncol Lett. 2017; 13: 141–50.

66. Zhao Q, Cai W, Zhang X, et al. Rybp expression is regulated by KLF4 and Sp1 and is related to hepatocellular carcinoma prognosis. J Biol Chem. 2017; 292: 2143–58.

67. Zhu X, Wang Z, Qiu X, et al. Associations between single nucleotide polymorphisms in Rybp and the prognosis of hepatocellular carcinoma in a Chinese population. Carcinogenesis. 2017; 38: 532–40.

68. Zhao G, Li Q, Wang A, et al. YY1 regulates melanoma tumorigenesis through a miR9–Rybp axis. J Exp Clin Cancer Res. 2015; 34: 66.

69. McGarry LC, Winnie JN, Ozanne BW. Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene. 2004; 23: 5284–92.

70. Zhao JL, Huang F, He F, et al. Forced activation of notch in macrophages represses tumor growth by upregulating miR-125a and disabling tumor-associated macrophages. Can Res. 2016; 76: 1403–15.

71. Biswas SK, Alleva P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Seminars in immunopathology. Berlin Heidelberg: Springer; 2013. pp. 585–600.

72. Blagoev B, Kratchmarova I, Ong S-E, et al. A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat Biotechnol. 2003; 21: 315–8.

73. Jin J, Smith FD, Stark C, et al. Protonic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol. 2004; 14: 1436–50.

74. Ho Y, Gruhler A, Heilbut A, et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature. 2002; 415: 180–3.

75. Egeland M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161–74.